Skip to content

A Sympathetic Ganglion, High-voltage Pulsed Radiofrequency Ablation of Peripheral Neuralgia

A Randomized, Controlled, Double-blind, Multicenter, Sympathetic Ganglion, High-voltage Pulsed Radiofrequency Ablation of Peripheral Neuralgia in Patients With Diabetic Foot

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05831059
Enrollment
60
Registered
2023-04-26
Start date
2022-12-12
Completion date
2024-12-15
Last updated
2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Brief summary

The Sham Operation Group was used as control, the patients were assessed with the Digital Rating Scale (NRS) , the quality of life-related scale (Euro Qol) , clinical outcome measures: physician's overall impression of changes in pain (CGIC) and patient's overall impression change scale (PGIC) , skin temperature measurement, toe Oxygenation measurement, and anxiety and depression scores (Gad-7, Phq-9) , objective: to evaluate the efficacy and safety of high voltage pulsed radiofrequency in the treatment of peripheral neuralgia in patients with diabetic foot.

Interventions

The means to achieve double-blind treatment had no practical effect on the subjects

RADIATIONPulsed radio frequency therapy

Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subjects voluntarily participate in the study and sign the informed consent form; * The age is between 18 (inclusive) and 85 (inclusive), regardless of gender; * Body mass index (BMI) ≤ 45; * Clinically diagnosed diabetes foot with moderate and severe pain in peripheral nerve of affected limb (defined as NRS score ≥ 4), the course of disease lasts for more than 12 months, and has been treated with clinical routine standard drugs (mecobalamin α- Lipoic acid, sodium valproate, carbamazepine, gabapentin/pregabalin, etc.) symptoms still exist at least 6 months later; * Glycated hemoglobin\<8%; * Not participating in the drug/medical device test within 3 months before the test;

Exclusion criteria

* Patients who are in poor condition and cannot objectively describe symptoms or cooperate to complete the questionnaire score * Ulcer is red and swollen, or active inflammatory infection; * The affected limb has lesions such as blackening and gangrene of the toe skin; * Those suffering from severe respiratory and cardiovascular diseases, liver and kidney insufficiency, and malignant tumors; * Breast-feeding and pregnant women, or subjects with pregnancy plan within 1 month after the trial (also including male subjects); * The daily dose of opioids is more than 120mg (different drug doses are converted into 120mg morphine sustained-release tablets); * People with allergic diseases and allergic constitution; * Have a history of drug abuse or drug addiction; * There are contraindications to pulsed radio frequency therapy;

Design outcomes

Primary

MeasureTime frameDescription
Numeric Rating Scaleup to 4 monthsNumeric Rating Scale is the most widely used one-dimensional assessment scale,The higher the number, the more severe the pain

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026